AF-DX 384 is an antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis = 6.03 and 10 nM, respectively). It is selective for M2 and M4 over M1, M3, and M5 receptors (Kis = 30.9, 66.07, and 537.03 nM, respectively). AF-DX 384 increases acetylcholine release in the hippocampus and cortex of young and aged rats in vivo when infused locally at a concentration of 1 μM and in the cortex when administered intraperitoneally at a dose of 5 mg/kg. It reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine .
ChEBI: N-[2-[2-[(dipropylamino)methyl]-1-piperidinyl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide is a benzodiazepine.